Search Results

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

The Wyss Center for Bio and Neuroengineering in Geneva and Dandelion Science are excited to announce a partnership focused on a cutting-edge generative AI neuromodulation platform that could speed the development of safe, non-invasive ways of treating neurodegenerative and neuropsychiatric disorders.

Children’s Hospital of Philadelphia is thrilled to announce a gift of $5 million from the Wyss Foundation to support innovations that improve the lives of patients with thoracic insufficiency syndrome.

Harvard Apparatus Regenerative Technology, Inc. announced that it officially executed a sponsored research agreement with Drs. Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.

NTT Research, Inc., a division of NTT, announced that the NTT Research Foundation, a 5013 organization, has made a gift to establish the Harvard University Center for Brain Science -NTT Fellowship Program in the new field of Physics of Intelligence.

The Feinstein Institutes for Medical Research has selected Michelle Monje, MD, PhD, from Stanford University, to receive the 11th annual Ross Prize in Molecular Medicine for her outstanding contributions to research relating to the neuroscience of cancer and its implications for therapy.

LIXTE Biotechnology Holdings, Inc. announced it is co-sponsoring an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Institute on May 9 and 10, 2024 in Boston, Massachusetts.

Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.